Intersect ENT Priced, Nasdaq: XENT
Sells absorbable nasal implants for post-surgical sinusitis relief.
Industry: Health Care
First Day Return: +17.5%
XENT
Sells absorbable nasal implants for post-surgical sinusitis relief.
| IPO Data | |
|---|---|
| IPO Date | 07/23/2014 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $55 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Menlo Park, CA, United States |
| Founded | 2003 |
| Employees at IPO | 146 |
| Website www.intersectent.com | |
IPO News for Intersect ENT
Intersect ENT (XENT) Performance
